Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

17 evidence topics · 16 sources

Summary
  • Durability: ICER's model analysis plan assumes that the treatment effect remains constant over the lifetime horizon and does not model discontinuation of a one-time gene therapy. Clinical experts noted that because neurons do not divide, the treatment effect may persist, while substantial uncertainty remains around long-term efficacy. ICER models TFC because there is no established mapping from the cUHDRS to costs, utilities, or mortality.
  • Endpoints: a decline of 1.2 points on the cUHDRS is recommended as an estimate of meaningful within-patient decline in early manifest HD. The sponsor reports that the FDA continued to support the cUHDRS as an acceptable registrational, intermediate clinical endpoint for accelerated approval, and a votoplam trial uses change from baseline up to month 36 in the cUHDRS as its primary endpoint. ICER's outcomes of interest include procedure-related adverse events (headache, complications, pain) and post lumbar puncture syndrome.
  • Interpretation of external comparisons: a placebo response in cognitive scores also influences the cUHDRS, and comparisons of trial data with retrospective natural history studies can mislead in distinguishing placebo response from drug effect. FDA draft guidance states that changes in the understanding of a disease's natural history can introduce bias in an externally controlled trial. Of forty-five FDA approvals that accepted external control data, retrospective natural history data were the most common source (44%) and 87% used an objective primary endpoint. Commentators cite a possible medical response bias from more frequent clinic visits, unmatched differences such as caudate and putamen size, and very small numbers of treated patients at longer follow-up, and state that assumptions about how long the benefit lasts will heavily shape modeled results.
  • Modeled long-term outcomes: in one model, hypothetical disease-modifying treatments led to cost savings in the PFD population and increased costs in the SF1 and SF2 populations by prolonging time spent in progressive HD states.